Special Issue

Targeting Breast Cancer: Mechanisms of Resistance and Innovative Therapeutic Strategies

Message from the Guest Editors

Breast cancer (BC) remains one of the most prevalent malignancies worldwide. Current treatment strategies focus on distinct molecular subtypes, including hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC). Endocrine therapies combined with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have significantly improved survival in patients with metastatic HR+ BC. Similarly, HER2-targeted agents like trastuzumab and pertuzumab have revolutionized the management of HER2-positive disease. While TNBC, which lacks these common therapeutic targets, remains a greater challenge. In this subtype, PARP inhibitors and immune checkpoint inhibitors are emerging as promising treatment options. Despite these advances, intrinsic and acquired resistance limit the long-term efficacy of current therapies.

In this Special Issue, we aim to provide a comprehensive overview of emerging therapeutic strategies for breast cancer, including novel molecular approaches to identify new targets and innovative combination therapies designed to overcome drug resistance.

Guest Editors

Dr. Stefania Belli

Dr. Daniela Esposito

Prof. Dr. Roberto Bianco

Deadline for manuscript submissions

15 January 2026

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/238256

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).